Oncology
Guidelines, trial intelligence, mechanisms and education across oncology practice, from tumour-specific updates to systemic anticancer therapy evidence.
Latest Guidelines
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
Test for MSI-H/dMMR before treatment: All patients with advanced or recurrent endometrial cancer should undergo microsatellite instability or mismatch repair deficiency testing prior to dostarlimab consideration,…
Lisocabtagene maraleucel for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment (terminated evaluation)
This NICE evaluation was terminated, meaning lisocabtagene maraleucel is not currently recommended for routine NHS use in relapsed or refractory follicular lymphoma—do not commission or initiate…
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma
First-line treatment option: Acalabrutinib combined with bendamustine and rituximab is recommended as a first-line treatment for untreated mantle cell lymphoma, offering an alternative to standard chemotherapy…
Acalabrutinib with venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia
Use acalabrutinib with venetoclax ± obinutuzumab as first-line treatment for untreated CLL – this combination is recommended by NICE and offers improved outcomes compared to standard…
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after an anti-androgen but not a taxane (terminated evaluation)
Evaluation terminated – NICE discontinued appraisal of lutetium-177 vipivotide tetraxetan; this agent is not recommended for routine NHS use and should not be prescribed outside approved…
Pembrolizumab with chemoradiotherapy for untreated locally advanced cervical cancer
Pembrolizumab combined with chemoradiotherapy is recommended for untreated locally advanced cervical cancer, improving survival outcomes compared to chemoradiotherapy alone—consider this combination as first-line treatment in eligible…
Trial Radar
EORTC Metastatic Breast Cancer Module Development
The overall aim of this project is to help improve the Health Related Quality of Life (HRQOL) of…
PHASE3Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
Adding talazoparib to enzalutamide improves outcomes in men with metastatic prostate cancer and DNA repair gene mutations.
PHASE3Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer
What is being tested: This phase 3 trial evaluates whether lower doses of Androgen Receptor Pathway Inhibitors (ARPIs)…
PHASE1Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
ORIC-114 is being tested as a novel therapeutic agent either alone or combined with chemotherapy in patients with…
Clinical News
‘I have chronic cancer but I’m not going to die’ – BBC presenter Maryam Moshiri
Polycythaemia vera should be considered in patients with unexplained blood count abnormalities; routine GP testing can identify the…
06 Sep 2026BBC News presenter reveals she has blood cancer
High-profile diagnosis raises public awareness of blood cancer, potentially increasing patient consultations and need for GPs to recognise…
02 Sep 2026Heart trial after breast cancer has ‘improved my life’
Women completing breast cancer treatment can safely discontinue cardioprotective medications (likely ACE inhibitors/beta-blockers) without adverse cardiac outcomes, based…
02 Sep 2026Urine test can spot more than nine in 10 bladder cancers
A novel urine test demonstrates >90% sensitivity for detecting bladder cancer, showing potential to improve early diagnosis in…
Relevant Mechanisms
BRAF/MEK Pathway — Melanoma
BRAF/MEK Pathway — Melanoma is a clinically relevant Drug Science explainer. The MAPK signalling cascade (RAS-RAF-MEK-ERK) transmits extracellular growth signals…
MechanismBTK Inhibition — B-cell Malignancies
BTK Inhibition — B-cell Malignancies is a clinically relevant Drug Science explainer. Bruton's tyrosine kinase (BTK) is a non-receptor cytoplasmic…
MechanismCDK4/6 Inhibition — Breast Cancer
CDK4/6 Inhibition — Breast Cancer is a clinically relevant Drug Science explainer. Cell cycle progression from G1 to S phase…
MechanismEGFR Pathway
EGFR Pathway is a clinically relevant Drug Science explainer. The epidermal growth factor receptor (EGFR/ErbB1/HER1) is a transmembrane receptor tyrosine…
MechanismHER2 Signalling
HER2 Signalling is a clinically relevant Drug Science explainer. Human epidermal growth factor receptor 2 (HER2/ErbB2) is a receptor tyrosine…
CPD, Podcasts & Webinars
No specialty-tagged education live yet
Oncology education appears here when podcasts, webinars and CPD modules are tagged to this hub.
Useful starting points in Oncology
EORTC Metastatic Breast Cancer Module Development
The overall aim of this project is to help improve the Health Related Quality of Life (HRQOL) of…
Clinical News‘I have chronic cancer but I’m not going to die’ – BBC presenter Maryam Moshiri
Polycythaemia vera should be considered in patients with unexplained blood count abnormalities; routine GP testing can identify the…
Clinical NewsBBC News presenter reveals she has blood cancer
High-profile diagnosis raises public awareness of blood cancer, potentially increasing patient consultations and need for GPs to recognise…
Education that still supports this area
SGLT2 Inhibitors: From Glycaemia to Heart Failure and Chronic Kidney Disease
recorded webinar focused on SGLT2 Inhibitors in diabetes and metabolic medicine. Use the recording with the slide outline…
WebinarJAK Inhibitors: Updated Safety Signals, Patient Selection and Post-ORAL Surveillance
Recorded webinar focused on JAK inhibitors in rheumatology and immune-mediated inflammatory disease. Reviews JAK-STAT signalling, patient selection, ORAL…
WebinarGLP-1 Agonists: Semaglutide, Tirzepatide and the Cardiovascular Revolution
recorded webinar focused on GLP-1 Agonists in diabetes and metabolic medicine. Use the recording with the slide outline…
Follow Oncology safety updates
Get MHRA safety alerts and clinically relevant updates for this specialty in your ClinicaliQ digest.
Follow Oncology
Choose guideline, trial, Drug Science and education updates for this specialty.